Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-01
2011-03-01
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
07897568
ABSTRACT:
Synthetic peptides containing an ankyrin repeat-like motif or portion thereof and mimetics thereof which interact with synuclein-gamma (SNCG) and reduce SNCG-mediated resistance of SNCG-expressing cancer cells to treatment with anticancer drugs or inhibit tumorigenesis and cancer cell proliferation are provided. Compositions containing these peptides, portions thereof or mimetics thereof are also provided. Methods for use of these peptides or portions thereof, compositions, and mimetics thereof in potentiating efficacy of anticancer drugs, in particular microtubule inhibitors and hormonal cancer therapies, and in treating cancer are also provided.
REFERENCES:
patent: 6225086 (2001-05-01), Morrow et al.
patent: 7008778 (2006-03-01), Ji et al.
patent: 7071309 (2006-07-01), Ji et al.
patent: 7417130 (2008-08-01), Stumpp et al.
patent: 2004/0146935 (2004-07-01), Roberts et al.
patent: 2007/0054268 (2007-03-01), Sutherland et al.
patent: 2007/0172462 (2007-07-01), Bohn et al.
patent: 00/34330 (2000-06-01), None
patent: 02/20565 (2002-03-01), None
patent: 2004/022778 (2004-03-01), None
patent: 2006/063397 (2005-06-01), None
patent: 2005/068661 (2005-07-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Blajeski et al. , “G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells”, J. Clin. Invest.2002 110(1):91-99.
Bruening et al., “Synucleins Are Expressed in the Majority of Breast and Ovarian Carcinomas and in Preneoplastic Lesions of the Ovary”, Cancer 2000 88:2154-2163.
Chan et al., “Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer”, J. Clin. Oncol 1999 17(8):2341-2354.
Choy et al., , “Probing Residual Interactions in Unfolded Protein States Using NMR Spin Relaxation Techniques:An Application to Delta131Delta”, J. Am. Chem. Soc. 2003 125:11988-11992.
Clayton, D.F. and George, J.M. “The synucleins:a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease”, Trends Neurosci. 1998 21(6):249-254.
Engelender et al., “Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions”, Nature Genetics 1999 22:110-114.
Elirzer et al., “Conformational Properties of alpha-Synuclein in its Free and Lipid-associated States”, J. Mol. Biol. 2001 307:1061-1073.
Gupta et al., “Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinse BubR1”, Oncogene 2003 22:7593-7599.
Iakoucheva et al., “Intrinsic Disorder in Cell-signaling and Cancer-associated Proteins”, J. Mol. Biol. 2002 323:573-584.
Inaba et al., “Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells”, Breast Cancer Res. Treat. 2005 94:25-35.
Ji et al., “Identification of a Breast Cancer-specific Gene, BCSG1, by Direct Differential cDNA Sequencing”, Cancer Res. 1997 57:759-764.
Jia et al., “Stimulation of Breast Cancer Invasion and Metastasis by Synuclein gamma”, Cancer Res. 1999 59:742-747.
Jiang et al., “Stimulation of Estrogen Receptor Signaling by gamma Synuclein”, Cancer Res. 2003 63:3899-3903.
Jiang et al., “Gamma Synuclein, a Novel Heat-Shock Protein-Associated Chaperone, Stimulates Ligand-Dependent Estrogen Receptor alpha Signaling and Mammary Tumorigenesis”, Cancer Res. 2004 64:4539-4546.
Kohl et al., “Designed to be stable:Crystal structure of a consensus ankyrin repeat protein”, Proc. Natl. Acad. Sci. USA 2003 100(4):1700-1705.
Lavedan et al., “Identification, localization and characterization of the human gamma-synuclein gene”, Hum Genet 1998 103:106-112.
Liu et al., “Transcriptional suppression of synuclein gamma (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M”, Breast Cancer Res. Treat. 2000 62:99-107.
Liu et al. “Loss of Epigenetic Control of Synuclein-gamma Gene as a Molecular Indicator of Metastasis in a Wide Range of Human Cancers”, Cancer Res. 2005 65(17):7635-7643.
Lu et al., “Blockade of API Transactivation Abrogates the Abnormal Expression of Breast Cancer-specific Gene 1 in Breast Cancer Cells”, J. Biol. Chem. 2002 277(35):31364-31372.
Mosavi et al., “The ankyrin repeat as molecular architecture for protein recognition”, Protein Science 2004 13:1435-1448.
Mosavi et al., “Consensus-derived structural determinants of the ankyrin repeat motif”, Proc. Natl. Acad. Sci. USA 2002 99(25):16029-16034.
Pan et al., “Gamma-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways”, J. Biol. Chem 2002 277(38):35050-35060.
Romero et al., “Natively Disordered Proteins—Functions and Predictions”, . Appl. Bioinformatics 2004 3(2-3):105-113.
Shin et al., “Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability”, Cancer Cell 2003 4:483-497.
Singh, V.K., et al., (2005) “You do not need to have ‘shape’ to get recognized: Story of natively unfolded gamma-synuclein interaction with ankyrin repeat”, FEBS Journal 272(sI): Abstract No. c6-006.
Tompa P., “Intrinsically unstructured proteins”, Trends Biochem. Sci. 2002 27(10):527-533.
Uversky V.N., “Natively unfolded proteins:A point where biology waits for physics”, Protein Sci. 2002 11:739-756.
Uversky et al., “Showing your ID:intrinsic disorder as an ID for recognition, regulation and cell signaling”, J. Mol. Recognit. 2005 18:343-384.
Valero et al., “A Phase II Study of Docetaxel in Patients With Paclitaxel-Resistant Metastatic Breast Cancer”, J. Clin. Oncol. 1998 16(10):3362-3368.
Wright et al., “Intrinsically Unstructured Proteins:Re-assessing the Protein Structure-Function Paradigm”, J. Mol. Biol. 1999 293:321-331.
Wu et al., “Stage-specific Expression of Breast Cancer-specific Gene gamma-Synuclein”, Cancer Epidemiol. Biomarkers Prev. 2003 12:920-925.
Yao et al., “NMR Stuctural and Dynamic Characterization of the Acid-Unfolded State of Apomyoglobin Provides Insights into the Early Events in Protein Folding”, Biochemistry 2001 40:3561-3571.
International Preliminary Report on Patentability dated Sep. 18, 2008.
Jia Zongchao
Singh Vinay K.
Huff Sheela J
Jia Zongchao
Licata & Tyrrell P.C.
Singh Vinay K.
LandOfFree
Compositions for treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2628958